Roche Reports registry Data for Tralokinumab in Melanoma

Roche today announced registry results for tralokinumab in patients with melanoma. The study demonstrated that tralokinumab reduces hospitalization rates compared to standard of care or placebo. These results provide important insights into the treatment of melanoma and support the continued development of tralokinumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.